- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01055002
A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers
A Pilot Phase II Study of the Efficacy of Antimalarial Drugs Against Plasmodium Falciparum by Experimental Challenge With a Low Dose of Blood Stage Parasites in Healthy Male Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-center, controlled, randomized, study using a BSP inoculum challenge as a model to assess the activity of antimalarial agents. The study will be conducted in 2 cohorts (n = 6 and n = 10). Cohort 2 will not commence until at least after day 12 of cohort 1 and review by Safety Review Team following day 9 exit of cohort 1. The participants will be randomized 1:1 to the two registered antimalarials. This is an enabling study using registered antimalarial drugs as reference treatments (one slow acting and one fast acting), aimed to inform trial design, endpoints and testing regimens for assessing new candidate antimalarial drugs in development. The study will follow the sequence of the challenge inoculation, reference treatment and follow-up.
Healthy male participants will be inoculated on Day 1 with ~1,800 Plasmodium falciparum-infected human erythrocytes administered intravenously. On an outpatient basis, participants will be monitored morning (AM) and night (PM) from day 3 to day 5 for adverse events and the unexpected early onset of symptoms, signs or parasitological evidence of malaria. On day 5 evening, participants will be admitted to the study unit and confined for safety monitoring and antimalarial treatment. Reference treatment administration will begin on the evening of Day 6 and continued on Day 7 and 8 (3 days of treatment).
If clinical or parasitologic evidence of malaria (either the identification of two or more malaria parasites on a malaria thick film, platelet count less than 100 x109/L, or the onset of clinical features of malaria) occurs before day 6 evening, allocated treatment will begin at this time.
Following treatment, participants will be followed up as inpatients for at least 86 hours, (4 evenings) to ensure tolerance of the therapy and clinical response, then if clinically well on an outpatient basis for safety and continued presence of malaria parasites via PCR and thick blood film review.
Adverse events will be monitored via telephone monitoring, within the clinical research unit and on outpatient review after malaria challenge inoculation and antimalarial study drug administration. Blood samples for safety evaluation, malaria monitoring, and red blood cell antibodies will be drawn at baseline and at nominated times after malaria challenge.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4006
- Q-Pharm Clinics, Royal Brisbane and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males aged 18-45 years who do not live alone
- BMI within 18-30
- Understand the procedures and risks involved
- Contactable for the duration of the study
- Non-smokers and in good health
- Good venous access
Exclusion Criteria:
- History of malaria
- Been in a malaria-endemic country within 12 months
- Evidence of cardiovascular risk
- Splenectomy
- History of severe allergic reactions after vaccination of infusion
- Any serious chronic illness
- Inherited genetic anomaly
- Any volunteers wishing to donate blood to the blood bank in the future
- Retinal or visual field changes
- Diagnosis of chronic severe psychiatric condition
- Hospitalisation within 5 years for psychiatric illness, suicide attempt or danger to self or others
- Receiving psychiatric drugs (some exceptions)
- Known QTc prolongation
- Family history of cardiac anomalies
- Recent or current therapy with an antibiotic or drug with potential antimalarial activity
- Known hypersensitivity to artemether or lumefantrine, atovaquone or proguanil hydrochloride or any of the excipients
- Concomitant use of any drug which is metabolised by the cytochrome enzyme CYP2D6 OR drugs that are known to prolong the QTc interval
- Use of corticosteroids, anti-inflammatory drugs, any immunomodulators or anticoagulants. Currently receiving or have previously received immunosuppressive therapy, including systemic steroids including ACTH or inhaled steroids in dosages which are associated with hypothalamicpituitary- adrenal axis suppression such as 1mg/kg/day of prednisone or its equivalent or chronic use of inhaled high potency corticosteroids
- Presence of acute infectious disease or fever
- Evidence of acute illness within the four weeks before trial prior to screening
- Significant intercurrent disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis
- Alcohol consumption greater than community norms
- A history of drug habituation, or any prior intravenous usage of an illicit substance
- Medical requirement for intravenous immunoglobulin or blood transfusions
- Participation in any investigational product study within the 8 weeks preceding the study
- Participation in any research study involving significant blood sampling, or blood donation to a blood bank during the 8 weeks preceding the study
- Have ever received a blood transfusion
- Positive test for HIV, Hepatitis B, hepatitis C, Human T-cell Lymphotropic Virus I & II (HTLVI & HTLVII), and syphilis
- Any clinically significant biochemical or haematologic abnormality (Hb must be ≥13.5g/dL)
- Ingestion of any poppy seeds within the 48 hours prior to the screening blood test
- Detection of any recreational drug listed in the urine drug screen
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Artemether/lumefantrine tablets
Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
|
Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
|
Active Comparator: Atovaquone/Proguanil HCl tablets
Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8
|
Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Parasite clearance rates by PCR
Time Frame: 1-7 days after drug treatment
|
1-7 days after drug treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Parasite growth rates by PCR
Time Frame: 1-6 days after inoculation
|
1-6 days after inoculation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James McCarthy, MD FRACP, Queensland Institute of Medical Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- QP09C08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Blood stage parasite (BSP) inoculum
-
University of OxfordWellcome TrustRecruitingPlasmodium Vivax InfectionThailand
-
University of OxfordActive, not recruiting
-
University of OxfordCompleted
-
CAS Lamvac Biotech Co., Ltd.Recruiting
-
CAS Lamvac Biotech Co., Ltd.RecruitingAdvanced Breast Cancer | Advanced Liver CancerChina
-
PfizerCompletedBacterial Infections | Staphylococcal Skin Infections | Staphylococcal Infections | Staphylococcal Vaccines | Immunotherapy, ActiveAustralia
-
State Key Laboratory of Respiratory DiseaseCAS Lamvac Biotech Co., Ltd.Recruiting
-
Timothy J Nelson, MD, PhDChildren's Hospital of Philadelphia; Children's Hospital Colorado; University... and other collaboratorsActive, not recruitingHypoplastic Left Heart SyndromeUnited States
-
Jonathan H. WatersHbO2 Therapeutics LLCAvailableAnemia SevereUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse... and other conditionsUnited States